Assenagon Asset Management S.A. Sells 54,791 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Assenagon Asset Management S.A. trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 68.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 25,590 shares of the biopharmaceutical company’s stock after selling 54,791 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Alnylam Pharmaceuticals were worth $10,176,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Root Financial Partners LLC acquired a new position in shares of Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Salomon & Ludwin LLC acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $27,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the third quarter valued at approximately $29,000. Ameriflex Group Inc. bought a new position in shares of Alnylam Pharmaceuticals during the third quarter worth approximately $32,000. Finally, ORG Partners LLC lifted its holdings in Alnylam Pharmaceuticals by 70.2% during the 3rd quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 33 shares during the last quarter. Institutional investors own 92.97% of the company’s stock.

Insiders Place Their Bets

In related news, EVP Tolga Tanguler sold 1,598 shares of the firm’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $523,584.70. Following the completion of the transaction, the executive vice president directly owned 36,606 shares of the company’s stock, valued at $11,993,955.90. This trade represents a 4.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Pushkal Garg sold 1,775 shares of Alnylam Pharmaceuticals stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $319.74, for a total value of $567,538.50. Following the transaction, the executive vice president directly owned 23,406 shares in the company, valued at $7,483,834.44. The trade was a 7.05% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 over the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts have weighed in on the stock. Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, February 17th. Raymond James Financial reissued an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. HC Wainwright restated a “buy” rating and set a $510.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Wednesday. Oppenheimer began coverage on Alnylam Pharmaceuticals in a report on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective for the company. Finally, Wall Street Zen downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, March 21st. One research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $468.84.

Alnylam Pharmaceuticals Stock Down 3.3%

NASDAQ:ALNY opened at $317.36 on Friday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71. The company has a market cap of $42.09 billion, a PE ratio of 185.59 and a beta of 0.36. The firm’s 50 day simple moving average is $330.67 and its 200 day simple moving average is $400.74.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.18). The business had revenue of $1.10 billion during the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company’s revenue was up 84.9% compared to the same quarter last year. During the same quarter last year, the company posted ($0.65) earnings per share. On average, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.